| 1 |
NCT00168870 |
Unknown † |
Study of Metastatic Ocular Melanoma |
|
- Drug: Gemcitabine
- Drug: Treosulfan
|
Interventional |
Phase 2 |
- Charite University, Berlin, Germany
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
- Time to progression
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT00168870 |
Haema CBF AHM UK/AS 04 |
|
February 2003 |
|
|
September 15, 2005 |
August 31, 2007 |
|
- Hematology & Oncology Charité CBF Berlin
Berlin, Germany
|
| 2 |
NCT01893099 |
Active, not recruiting |
Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma |
|
- Drug: Sorafenib
- Device: Radioembolization with SIR-Spheres® (Yttrium Microspheres)
|
Interventional |
Phase 1 |
- Centre Hospitalier Universitaire Vaudois
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity
- Translational research on biomarkers
- Clinical benefit
- (and 2 more...)
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT01893099 |
CHUV-CePO-code 16295 |
|
June 2013 |
December 2017 |
December 2017 |
July 8, 2013 |
August 23, 2017 |
|
- Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
|
| 3 |
NCT01200238 |
Active, not recruiting |
STA-9090(Ganetespib) in Metastatic Ocular Melanoma |
|
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Beth Israel Deaconess Medical Center
- Massachusetts General Hospital
- (and 2 more...)
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival Rate
- Expression of cMET
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT01200238 |
10-137 |
|
June 2010 |
May 14, 2016 |
June 2019 |
September 13, 2010 |
February 1, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 4 |
NCT00621439 |
Withdrawn |
Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye |
|
- Drug: Pegylated Interfon Alpha 2B
- Drug: Placebo
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Evidence of anti-melanoma natural killer cell boost
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT00621439 |
IRB00002566 |
|
March 2007 |
June 2008 |
|
February 22, 2008 |
December 2, 2013 |
|
|
| 5 |
NCT01814046 |
Completed
Has Results |
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma |
- Metastatic Ocular Melanoma
- Metastatic Uveal Melanoma
|
- Drug: Aldesleukin
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Biological: Young Tumor Infiltrating Lymphocytes (TIL)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Ocular Melanoma Treated With Young Tumor Infiltrating Lymphocytes (TIL) With or Without High Dose Aldesleukin With an Objective Response Rate of (Complete Response (CR) + Partial Response (PR))
- Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0)
|
24 |
All |
16 Years to 75 Years (Child, Adult, Senior) |
NCT01814046 |
130093
13-C-0093 |
|
March 1, 2013 |
May 1, 2017 |
May 31, 2017 |
March 19, 2013 |
January 23, 2018 |
July 24, 2017 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 6 |
NCT01930968 |
Not yet recruiting |
Definity for Ultrasound of Intraocular Tumors |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Quantification of tumor perfusion and visualization of microvasculature using ultrasound enhanced images of intraocular tumors with microbubbles
- Correlation between tumor vascularity by contrast enhanced ultrasoungraphy and histologically determined tumor vascular density
- Correlation between tumor size by contrast enhanced ultrasoungraphy and histologically determined tumor size
|
10 |
All |
20 Years and older (Adult, Senior) |
NCT01930968 |
IRB00039493 |
|
January 2019 |
December 2019 |
December 2019 |
August 29, 2013 |
February 28, 2018 |
|
- Emory Eye Center
Atlanta, Georgia, United States
|
| 7 |
NCT01355120 |
Completed |
THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease |
|
|
Interventional |
Phase 2 |
- Prof. Dr. med. Dirk Schadendorf
- University Hospital, Essen
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- safety and efficacy parameters
- Efficacy according to immune-related response criteria (ir-RC) at any time during treatment
- (and 6 more...)
|
171 |
All |
18 Years and older (Adult, Senior) |
NCT01355120 |
DeCOG -MM-PAL11 |
DeCOG |
October 2011 |
September 2012 |
September 2013 |
May 17, 2011 |
June 23, 2014 |
|
- Universitätsklinikum Erlangen Hautklinik
Erlangen, Bayern, Germany - Klinikum Nürnberg Nord
Nürnberg, Bayern, Germany - Klinikum Kassel GmbH
Kassel, Hessen, Germany - (and 22 more...)
|
| 8 |
NCT00346372 |
Recruiting |
Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy |
|
|
Observational |
|
- Jonsson Comprehensive Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
800 |
All |
18 Years and older (Adult, Senior) |
NCT00346372 |
UCLA IRB#03-11-052 |
|
March 2004 |
December 2019 |
January 2021 |
June 29, 2006 |
January 4, 2018 |
|
- Jules Stein Eye Institute
Los Angeles, California, United States
|
| 9 |
NCT03172299 |
Not yet recruiting |
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma |
|
- Drug: Aflibercept Injection
- Drug: False injection
|
Interventional |
Phase 3 |
- Centre Hospitalier Universitaire de Nice
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Occurrence of neovascular glaucoma
|
56 |
All |
18 Years and older (Adult, Senior) |
NCT03172299 |
15-API-01 |
PROTECT |
June 2017 |
June 2024 |
December 2024 |
June 1, 2017 |
June 7, 2017 |
|
|
| 10 |
NCT02909517 |
Recruiting |
The Role of Inflammation in Ocular Tumours |
|
|
Observational |
|
- St. Michael's Hospital, Toronto
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identification of macrophages
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02909517 |
14-416 |
|
March 2016 |
February 2017 |
|
September 21, 2016 |
September 21, 2016 |
|
- St Michael's Hospital
Toronto, Ontario, Canada - Princess Margaret Cancer Centre, Ontario
Toronto, Ontario, Canada
|
| 11 |
NCT00344799 |
Recruiting |
Cytogenetic Study of Ocular Melanoma |
|
|
Observational |
|
- Jonsson Comprehensive Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT00344799 |
UCLA IRB#04-12-084 |
|
January 8, 2005 |
August 31, 2020 |
August 31, 2021 |
June 27, 2006 |
September 13, 2017 |
|
- Jules Stein Eye Institute
Los Angeles, California, United States
|
| 12 |
NCT00351728 |
Completed |
Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone |
- Ocular Melanoma
- Choroidal Melanoma
- Uveal Melanoma
|
|
Observational |
|
- Jonsson Comprehensive Cancer Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
174 |
All |
18 Years and older (Adult, Senior) |
NCT00351728 |
UCLA IRB #05-04-016 |
|
June 2006 |
August 2012 |
August 2012 |
July 13, 2006 |
July 7, 2016 |
|
- Jules Stein Eye Institute
Los Angeles, California, United States
|
| 13 |
NCT00109005 |
Completed
Has Results |
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma |
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Responses in Patients With Metastatic Ocular Melanoma
- Number of Participants With Adverse Events
- Progression Free Survival
- (and 4 more...)
|
17 |
All |
18 Years and older (Adult, Senior) |
NCT00109005 |
050095
05-C-0095 |
|
April 2005 |
April 2009 |
April 2009 |
April 22, 2005 |
January 2, 2017 |
October 30, 2012 |
- National Cancer Institute (NCI)
Bethesda, Maryland, United States
|
| 14 |
NCT00062933 |
Completed |
A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma |
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT00062933 |
030221
03-C-0221 |
|
June 2003 |
September 2007 |
March 2008 |
June 18, 2003 |
August 20, 2012 |
|
- National Cancer Institute (NCI)
Bethesda, Maryland, United States
|
| 15 |
NCT02678572 |
Recruiting |
Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma |
|
- Procedure: Melphalan
- Procedure: TACE
- Drug: Dacarbazine
- (and 2 more...)
|
Interventional |
Phase 3 |
- Delcath Systems Inc.
- Novella Clinical
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Progression Free Survival (PFS) as determined by Investigator
- Objective Response Rate (ORR) as determined by Investigator
|
240 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02678572 |
PHP-OCM-301 |
FOCUS |
January 2015 |
June 2019 |
June 2019 |
February 10, 2016 |
January 31, 2018 |
|
- Stanford University
Palo Alto, California, United States - Moffitt Cancer Center
Tampa, Florida, United States - Emory University
Atlanta, Georgia, United States - (and 28 more...)
|
| 16 |
NCT00421317 |
Terminated |
Imatinib in Adult Patients With Metastatic Ocular Melanoma |
|
|
Interventional |
Phase 2 |
- Centre Oscar Lambret
- Novartis
- National Cancer Institute, France
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free rate at 3 months
- Progression-free rate at 6 and 12 months
- Response rate according to RECIST criteria
- (and 3 more...)
|
13 |
All |
18 Years and older (Adult, Senior) |
NCT00421317 |
O-Mel-Inib 0508 |
O-Mel-Inib |
December 2005 |
March 2007 |
March 2007 |
January 11, 2007 |
January 6, 2016 |
|
- Centre Francois Baclesse
Caen, France - Centre Jean Perrin
Clermont-Ferrand, France - Centre Georges-Francois Leclerc
Dijon, France - (and 9 more...)
|
| 17 |
NCT00489944 |
Unknown † |
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma |
|
- Drug: cisplatin
- Drug: sunitinib malate
- Drug: tamoxifen citrate
- Procedure: adjuvant therapy
|
Interventional |
Phase 2 |
- San Diego Pacific Oncology & Hematology Associates
- National Cancer Institute (NCI)
|
Other |
- Primary Purpose: Treatment
|
- Disease-free survival
- Overall survival
- Toxicity
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT00489944 |
CDR0000551559
POHA-0604 |
|
May 2007 |
December 2012 |
|
June 21, 2007 |
January 10, 2014 |
|
- San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas
Encinitas, California, United States
|
| 18 |
NCT00085306 |
Completed |
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma |
- Stage IV Melanoma
- Recurrent Melanoma
|
- Biological: recombinant interferon beta
|
Interventional |
Phase 2 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective clinical response rate to IFN-B the maximum tolerated dose as measured by a CTC Grade III hematologic or a Grade IV granulocyte toxicity which persists > 3 days at 1 week after each course
|
21 |
All |
18 Years and older (Adult, Senior) |
NCT00085306 |
CASE1604
P30CA043703
CCF-4049 |
|
April 2004 |
October 2007 |
October 2007 |
June 11, 2004 |
October 2, 2015 |
|
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
| 19 |
NCT01587352 |
Suspended |
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye |
- Ocular Melanoma With Extraocular Extension
- Recurrent Uveal Melanoma
- Stage IV Uveal Melanoma AJCC v7
|
- Other: Laboratory Biomarker Analysis
- Drug: Vorinostat
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- Institut Curie Paris
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center P2C
|
NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate in patients with GNAQ/GNA11 mutant uveal melanoma, defined as the rate of complete and partial responses
- BAP1 mutation status
- GNA11 mutation status
- (and 4 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT01587352 |
NCI-2012-00860
CUMC-IRBAAAO5917
AAAO5917
MSKCC-12-027
9111
N01CM00100
N01CM62206
P30CA013696
U01CA069856
UM1CA186689 |
|
April 20, 2012 |
November 20, 2017 |
|
April 30, 2012 |
November 21, 2017 |
|
- Columbia University/Herbert Irving Cancer Center
New York, New York, United States - Memorial Sloan-Kettering Cancer Center
New York, New York, United States - Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, United States
|
| 20 |
NCT01835145 |
Completed |
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery |
- Recurrent Uveal Melanoma
- Stage III Uveal Melanoma AJCC v7
- Stage IIIA Uveal Melanoma AJCC v7
- (and 3 more...)
|
- Drug: Cabozantinib S-malate
- Drug: Dacarbazine
- Other: Laboratory Biomarker Analysis
- Drug: Temozolomide
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- Exelisis
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS4
- Confirmed response rate as determined by the RECIST criteria (version 1.1)
- Maximum grade for each type of adverse event, graded according to the National Cancer Institute CTCAE version 4.0
- (and 2 more...)
|
47 |
All |
18 Years and older (Adult, Senior) |
NCT01835145 |
NCI-2013-00821
CALGB-A091201
A091201
U10CA180821
U10CA031946 |
|
July 31, 2013 |
October 21, 2016 |
October 21, 2016 |
April 18, 2013 |
February 28, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 226 more...)
|
| 21 |
NCT00020475 |
Completed |
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye |
- Extraocular Extension Melanoma
- Recurrent Intraocular Melanoma
|
- Drug: gp100 antigen
- Drug: interleukin-2
- Drug: MART-1 antigen
- Drug: Montanide ISA-51
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
|
|
|
16 Years and older (Child, Adult, Senior) |
NCT00020475 |
CDR0000068514
NCI-01-C-0074
NCI-2910 |
|
February 2001 |
|
March 2007 |
March 6, 2007 |
August 16, 2013 |
|
- Surgery Branch
Bethesda, Maryland, United States
|
| 22 |
NCT00003802 |
Completed |
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma |
- Intraocular Melanoma
- Melanoma (Skin)
|
|
Interventional |
Phase 2 |
- Sidney Kimmel Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00003802 |
JHOC-J9875, CDR0000066946
U01CA063437
P30CA006973
JHOC-98111005
JHOC-JH9875
JHOC-T96-0116
NCI-T96-0116 |
|
February 1999 |
|
October 2002 |
May 2, 2003 |
December 17, 2012 |
|
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
|
| 23 |
NCT00482911 |
Terminated
Has Results |
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma |
- Intraocular Melanoma
- Malignant Conjunctival Neoplasm
|
- Drug: cyclophosphamide
- Drug: lenalidomide
- Drug: sunitinib malate
|
Interventional |
Phase 2 |
- National Institutes of Health Clinical Center (CC)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate (Complete and Partial Response)
- Toxicity
- Overall Survival
- (and 2 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT00482911 |
070134
NCI-07-C-0134 |
|
April 2007 |
April 2009 |
April 2009 |
June 5, 2007 |
March 27, 2017 |
November 14, 2012 |
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States
|
| 24 |
NCT00036816 |
Terminated |
Vaccine Therapy in Treating Patients With Melanoma of the Eye |
|
- Biological: MART-1 antigen
- Biological: NA17-A antigen
- Biological: gp100 antigen
- Biological: tyrosinase peptide
|
Interventional |
Phase 3 |
- European Organisation for Research and Treatment of Cancer - EORTC
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
13 |
All |
18 Years and older (Adult, Senior) |
NCT00036816 |
EORTC-18001 -88001
EORTC-18001
EORTC-88001 |
|
February 2002 |
February 2003 |
|
January 27, 2003 |
September 24, 2012 |
|
- Cliniques Universitaires Saint-Luc
Brussels, Belgium - University of Copenhagen
Copenhagen, Denmark
|
| 25 |
NCT00000124 |
Unknown † |
Collaborative Ocular Melanoma Study (COMS) |
|
- Procedure: Brachytherapy
- Procedure: Eye Removal
|
Interventional |
Phase 3 |
- National Eye Institute (NEI)
|
NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
|
All |
21 Years and older (Adult, Senior) |
NCT00000124 |
NEI-23 |
|
November 1986 |
|
|
September 24, 1999 |
June 2, 2006 |
|
|
| 26 |
NCT03052127 |
Recruiting |
Phase 1B/2 Study in Subjects With Small to Medium Primary Choroidal Melanoma |
- Uveal Melanoma
- Ocular Melanoma
- Choroidal Melanoma
|
- Drug: Light-activated AU-011
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of Light-activated AU-011
- Immunogenicity
- Preliminary efficacy
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT03052127 |
AU-011-101 |
|
February 27, 2017 |
March 2020 |
March 2020 |
February 14, 2017 |
March 23, 2018 |
|
- UCLA Jules Stein Eye Institute
Los Angeles, California, United States - Colorado Retina Associates
Denver, Colorado, United States - Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States - (and 6 more...)
|
| 27 |
NCT01728051 |
No longer available |
Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver |
- Metastatic Liver Cancer
- Ocular Melanoma
- Cutaneous Melanoma
|
- Drug: Melphalan
- Device: Percutaneous Hepatic Perfusion
|
Expanded Access |
|
|
Industry |
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT01728051 |
MEL 2009-01 |
|
|
|
|
November 16, 2012 |
October 23, 2013 |
|
- John Wayne Cancer Institute at Saint John's Health Center
Santa Monica, California, United States - Sky Ridge Medical Center
Englewood, Colorado, United States - H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
Tampa, Florida, United States - (and 3 more...)
|
| 28 |
NCT01143402 |
Completed
Has Results |
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye |
- Iris Melanoma
- Medium/Large Size Posterior Uveal Melanoma
- Ocular Melanoma With Extraocular Extension
- (and 3 more...)
|
- Drug: Dacarbazine
- Other: Laboratory Biomarker Analysis
- Other: Quality-of-Life Assessment
- (and 2 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival (PFS) (Evaluable Randomized Patients)
- Median Overall Survival (Evaluable Randomized Patients)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT01143402 |
NCI-2011-01411
CDR0000674866
10-053
8443
N01CM00070
N01CM00071
N01CM00099
N01CM00100
N01CM62206
N01CM62208
P30CA008748
U01CA132123 |
|
June 2010 |
May 2016 |
May 2016 |
June 14, 2010 |
July 26, 2017 |
May 18, 2017 |
- University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, United States - Mount Sinai Medical Center
Miami Beach, Florida, United States - Moffitt Cancer Center
Tampa, Florida, United States - (and 30 more...)
|
| 29 |
NCT00244816 |
Completed |
Taxoprexin® Treatment for Advanced Eye Melanoma |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Time to progression
- Time to treatment failure
- Survival
|
30 |
All |
13 Years and older (Child, Adult, Senior) |
NCT00244816 |
P01-04-22 |
|
October 2005 |
|
April 2007 |
October 27, 2005 |
January 24, 2018 |
|
- MD Anderson Cancer Center
Houston, Texas, United States
|
| 30 |
NCT02697630 |
Recruiting |
Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye |
- Metastatic Uveal Melanoma
|
- Drug: Pembrolizumab
- Drug: Entinostat
|
Interventional |
Phase 2 |
- Vastra Gotaland Region
- Merck Sharp & Dohme Corp.
- Syndax Pharmaceuticals
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
- Clinical benefit rate (CBR)
- Progression free survival (PFS)
- (and 8 more...)
|
29 |
All |
18 Years and older (Adult, Senior) |
NCT02697630 |
2016-1 |
PEMDAC |
February 21, 2018 |
August 2021 |
August 2023 |
March 3, 2016 |
February 23, 2018 |
|
- Department of oncology, Sahlgrenska University Hospital
Gothenburg, Västra Götaland Region, Sweden
|
| 31 |
NCT01413191 |
Completed
Has Results |
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye |
- Ciliary Body and Choroid Melanoma, Medium/Large Size
- Ciliary Body and Choroid Melanoma, Small Size
- Iris Melanoma
- (and 3 more...)
|
- Biological: Cixutumumab
- Other: Laboratory biomarker analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate (% Participants With Complete or Partial Response)
- Disease Control Rate (i.e., the Proportion of Subjects With a Confirmed Complete or Partial Response of Any Duration or Stable Disease ≥3 Months in Duration)
- Durable Response Rate (i.e., the Proportion of Subjects With a Confirmed Complete or Partial Response ≥ 6 Months in Duration)
- (and 4 more...)
|
18 |
All |
17 Years and older (Child, Adult, Senior) |
NCT01413191 |
NCI-2011-02228
2010-0451
8832
P30CA016672
N01CM00039 |
|
August 2011 |
March 2013 |
June 2014 |
August 10, 2011 |
July 20, 2015 |
July 20, 2015 |
- Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States - M D Anderson Cancer Center
Houston, Texas, United States
|
| 32 |
NCT00406120 |
Withdrawn |
Validation of a Molecular Prognostic Test for Eye Melanoma |
- Uveal Neoplasms
- Choroid Neoplasms
- Iris Neoplasms
|
- Procedure: Fine needle aspiration biopsy
|
Observational |
|
- Washington University School of Medicine
|
Other |
- Observational Model: Defined Population
- Time Perspective: Longitudinal
- Time Perspective: Prospective
|
|
2000 |
All |
Child, Adult, Senior |
NCT00406120 |
98-0042-A |
|
January 2007 |
|
December 2017 |
December 4, 2006 |
May 17, 2007 |
|
- Washington University School of Medicine
St. Louis, Missouri, United States
|
| 33 |
NCT01217398 |
Unknown † |
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye |
|
- Biological: bevacizumab
- Drug: temozolomide
- Genetic: polymorphism analysis
- Other: pharmacogenomic studies
|
Interventional |
Phase 2 |
- Institut Curie
- National Cancer Institute (NCI)
|
Other |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease control rate, in terms of objective response rate and the stable disease rate determined according to RECIST criteria at 6 months
- Response rate
- Duration of response
- (and 4 more...)
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT01217398 |
CDR0000683852
CLCC-IC-2009-01
EUDRACT-2009-011751-46
EU-21063 |
|
October 2009 |
October 2012 |
|
October 8, 2010 |
August 26, 2013 |
|
- Institut Curie Hopital
Paris, France
|
| 34 |
NCT00952939 |
Completed |
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye |
|
- Genetic: fluorescence in situ hybridization
- Other: laboratory biomarker analysis
- Procedure: fine-needle aspiration
- (and 2 more...)
|
Observational |
|
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Number of patients that have Disease Free Survival (DFS) with primary uveal melanoma with and without high-risk genotypes
- Number of patients with adverse events to determine ophthalmic complication rate of FNA for FISH analysis in patients undergoing plaque radiotherapy.
- The rate that sufficient tissue can be obtained by FNA.
- distribution of particular markers at specific timepoints
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT00952939 |
CASE5608
P30CA043703
CASE 5608-CC666 |
|
March 2009 |
September 2012 |
February 2014 |
August 6, 2009 |
January 30, 2015 |
|
- Cleveland Clinic Cole Eye Institute
Cleveland, Ohio, United States
|
| 35 |
NCT00329641 |
Completed
Has Results |
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye |
- Ciliary Body and Choroid Melanoma, Medium/Large Size
- Extraocular Extension Melanoma
- Iris Melanoma
- (and 2 more...)
|
- Drug: carboplatin
- Drug: paclitaxel
- Drug: sorafenib tosylate
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate (Complete and Partial Response)
- One-year Overall Survival
- 6-month Progression-free Survival
- Toxicity
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT00329641 |
NCI-2009-00777
CDR0000467188
S0512
U10CA032102 |
|
February 2011 |
November 2012 |
November 2012 |
May 25, 2006 |
July 31, 2014 |
July 11, 2012 |
- Southwest Oncology Group
San Antonio, Texas, United States
|
| 36 |
NCT00738361 |
Completed
Has Results |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery |
|
|
Interventional |
Phase 2 |
- Ohio State University Comprehensive Cancer Center
- National Comprehensive Cancer Network
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Progression-free Survival
- Overall Survival
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT00738361 |
OSU-08076
NCI-2011-03176 |
|
August 2008 |
July 2012 |
April 2013 |
August 20, 2008 |
February 12, 2016 |
February 12, 2016 |
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
| 37 |
NCT00110123 |
Terminated |
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma |
- Intraocular Melanoma
- Metastatic Cancer
|
- Drug: fotemustine
- Drug: isolated perfusion
|
Interventional |
Phase 3 |
- European Organisation for Research and Treatment of Cancer - EORTC
|
Other |
- Allocation: Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Duration of survival
- Progression-free survival
- Best response as assessed by RECIST criteria
- (and 2 more...)
|
171 |
All |
18 Years and older (Adult, Senior) |
NCT00110123 |
EORTC-18021
2004-002245-12 |
|
January 2005 |
June 2011 |
|
May 4, 2005 |
September 24, 2012 |
|
- European Institute of Oncology
Milan, Italy - Istituto Nazionale per lo Studio e la Cura dei Tumori
Naples, Italy - Azienda Ospedaliera di Padova
Padova, Italy - (and 5 more...)
|
| 38 |
NCT02858869 |
Recruiting |
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases |
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Melanoma
- Mucosal Melanoma
- (and 3 more...)
|
- Biological: Pembrolizumab
- Radiation: Stereotactic Radiosurgery
|
Interventional |
Phase 1 |
- Emory University
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of dose limiting toxicities defined as Radiation Therapy Oncology Group grade 3 central nervous system toxicities which are irreversible severe neurological symptoms requiring medications
- Frequency and absolute cell counts for pre and post treatment serum immune biomarkers
- Overall response (intra-cranial and extra-cranial) assessed using RECIST and immune RECIST Criteria
- (and 5 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02858869 |
IRB00086461
NCI-2016-00718
RAD3179-16 |
|
October 4, 2016 |
October 2019 |
October 2020 |
August 8, 2016 |
January 16, 2018 |
|
- Emory University/Winship Cancer Institute
Atlanta, Georgia, United States
|
| 39 |
NCT02129075 |
Suspended |
CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma |
- Cutaneous Melanoma
- Mucosal Melanoma
- NY-ESO-1 Positive Tumor Cells Present
- (and 8 more...)
|
- Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- Other: Laboratory Biomarker Analysis
- Biological: Neoantigen-based Melanoma-Poly-ICLC Vaccine
- (and 2 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Immune T-cell response to NY-ESO-1
- T cell responses to other ongoing and nascent antitumor response antigens associated with melanoma (e.g. PRAME, MAGE-A3, p53, and gp1000) as well as memory and chronic viral responses (CMV, EBV)
- Frequency and phenotypic character of PBMC subsets including DCs, monocyte populations, T cells, and NK cells
- (and 5 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT02129075 |
NCI-2014-00898
s14-01284
CITN-07-FLT3L
P30CA015704
U01CA154967 |
|
April 9, 2014 |
February 2, 2020 |
|
May 2, 2014 |
March 13, 2018 |
|
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States - Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, United States - Mount Sinai Hospital
New York, New York, United States - (and 4 more...)
|
| 40 |
NCT02376920 |
Active, not recruiting |
5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes |
|
|
Observational |
|
- Castle Biosciences Incorporated
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- documentation of clinical application of results obtained from DecisionDx-UM multi-gene assay
- Time to metastasis
- changes in health care costs
|
2800 |
All |
16 Years and older (Child, Adult, Senior) |
NCT02376920 |
2-01 |
CLEAR |
March 2010 |
October 2020 |
October 2020 |
March 3, 2015 |
January 25, 2018 |
|
|
| 41 |
NCT01801358 |
Terminated
Has Results |
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma |
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle
- Phase II: Progression Free Survival (PFS)
- Phase Ib/II: The Number of Subjects Experiencing At Least One Adverse Event (AE)
- (and 20 more...)
|
38 |
All |
18 Years and older (Adult, Senior) |
NCT01801358 |
CMEK162X2203 |
|
August 2013 |
May 2015 |
May 2015 |
February 28, 2013 |
October 20, 2016 |
October 20, 2016 |
- Dana Farber Cancer Institute Dept. Onc
Boston, Massachusetts, United States - Memorial Sloan Kettering Cancer Center Dept of Onc..
NY, New York, United States - Novartis Investigative Site
Paris, France - (and 4 more...)
|
| 42 |
NCT02315066 |
Recruiting |
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 |
|
- Drug: PF-04518600
- Drug: PF-04518600 plus PF-05082566
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Dose-limiting toxicities (DLT) [Dose Escalation]
- Overall safety profile [Dose Expansion]
- Incidence of anti-drug antibodies and neutralization assays
- (and 4 more...)
|
210 |
All |
18 Years and older (Adult, Senior) |
NCT02315066 |
B0601002
2014-004107-75 |
|
April 2015 |
December 2018 |
August 2020 |
December 11, 2014 |
March 8, 2018 |
|
- Clinical Research Unit
Los Angeles, California, United States - The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate
Los Angeles, California, United States - Keck Hospital of USC
Los Angeles, California, United States - (and 33 more...)
|
| 43 |
NCT01473004 |
Active, not recruiting |
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver |
|
|
Interventional |
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical benefit rate of previously treated and naive patients
- Number of patients with adverse events
- Overall Survival
- (and 2 more...)
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT01473004 |
10D.95 |
|
October 31, 2011 |
January 1, 2019 |
January 1, 2020 |
November 17, 2011 |
November 13, 2017 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 44 |
NCT01046487 |
Completed |
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate |
|
- Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 1 )
- Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 2)
- Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 3)
- Procedure: Blood sampling
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- For safety: NCI-CTCAE scale version 3.0
- For anti tumoral efficiency : RECIST criteria
|
26 |
All |
18 Years and older (Adult, Senior) |
NCT01046487 |
PALANGI-3 0804 |
PALANGI3 |
January 2009 |
April 2011 |
February 2012 |
January 12, 2010 |
June 7, 2012 |
|
- Institut Bergonié
Bordeaux, France - Centre Oscar Lambret
Lille, France - Centre Léon Bérard
Lyon, France
|
Create an RSS feed from your search for:
Download the search results for: